A proprietary monoclonal antibody targeting an inhibitory immune checkpoint pathway had favorable safety and tolerability in ...
Stocktwits on MSN
IBRX stock is back: Anktiva now targets severe pneumonia after clearing key checkpoint in bladder cancer trial
The founder said that 50% of enrolled patients in the Phase 3 bladder cancer study reached an evaluable efficacy endpoint, ...
The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
Akeso, Inc. (9926.HK) ('Akeso' or the 'Company') announced today that it has received clearance from the Center for Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results